Compare Stocks

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$1.04 -1.7%	$1.39	$0.42 ▼ $2.05	$172.64M	2.39	1.74 million shs	602,613 shs
APTO Aptose Biosciences	$1.23 +6.0%	$1.56	$1.15 ▼ $8.70	$19.34M	1.29	86,995 shs	75,015 shs
GMDA Gamida Cell	$0.02	$0.22	$0.03 ▼ $2.51	$2.77M	0.93	9.20 million shs	405,165 shs
JNCE Jounce Therapeutics	$1.88 -2.6%	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	11.60 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-1.85%	+17.99%	-30.26%	+45.21%	-22.06%
APTO Aptose Biosciences	-4.92%	-8.66%	-27.50%	-41.41%	-83.67%
GMDA Gamida Cell	+2.65%	-0.64%	-95.48%	-95.75%	-98.99%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	-2.59%

A new way to collect income from stocks (Ad)

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	1.1146 of 5 stars	2.5	3.0	0.0	0.0	2.3	0.8	0.6
APTO Aptose Biosciences	2.8219 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.0	0.6
GMDA Gamida Cell	0.6768 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.8	0.0
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	1.00	Sell	$2.50	139.99% Upside
APTO Aptose Biosciences	3.00	Buy	$19.80	1,509.76% Upside
GMDA Gamida Cell	2.75	Moderate Buy	$4.75	26,288.89% Upside
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest APTO, JNCE, GMDA, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$5.00
3/27/2024	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
2/1/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $5.00
1/29/2024	GMDA Gamida Cell	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$60.28M	2.86	N/A	N/A	$0.04 per share	26.04
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
GMDA Gamida Cell	$1.78M	1.55	N/A	N/A	($0.02) per share	-0.90
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.55	N/A	N/A	N/A	-188.90%	-155.39%	-43.42%	5/10/2024 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$7.72	N/A	N/A	N/A	N/A	-458.70%	-205.30%	5/13/2024 (Estimated)
GMDA Gamida Cell	-$63M	-$0.63	N/A	∞	N/A	N/A	N/A	-57.59%	5/20/2024 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A

Latest APTO, JNCE, GMDA, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APTO Aptose Biosciences	-$1.48	-$1.44	+$0.04	-$1.44	N/A	N/A
3/6/2024	Q4 2023	ADAP Adaptimmune Therapeutics	-$0.12	-$0.24	-$0.12	-$0.24	$4.80 million	$0.23 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	N/A	2.85	2.85
APTO Aptose Biosciences	N/A	0.78	0.78
GMDA Gamida Cell	213.14	2.16	2.09
JNCE Jounce Therapeutics	N/A	8.37	8.37

Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
APTO Aptose Biosciences	26.62%
GMDA Gamida Cell	50.34%
JNCE Jounce Therapeutics	80.66%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
APTO Aptose Biosciences	9.53%
GMDA Gamida Cell	3.40%
JNCE Jounce Therapeutics	6.92%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	449	165.73 million	870.53 million	Optionable
APTO Aptose Biosciences	31	15.72 million	14.22 million	No Data
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable

APTO, JNCE, GMDA, and ADAP Headlines

Source	Headline
	Jounce Therapeutics gets grant for monoclonal antibody for treating cancer by binding PD-1 pharmaceutical-technology.com - April 15 at 12:47 PM
	Multimatic Jounce Control Dampers Now Available For Chevy Colorado ZR2 gmauthority.com - April 13 at 9:57 AM
	2024 Jeep Gladiator Mojave Keeps On Truckin' caranddriver.com - April 8 at 7:30 PM
	San Diego VC, OrbiMed make competing buyout offers for struggling Theseus bizjournals.com - November 27 at 12:12 PM
	Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source tmcnet.com - September 19 at 2:48 PM
	Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media finance.yahoo.com - September 18 at 2:58 PM
	Mediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Media tmcnet.com - September 5 at 5:55 PM
	Board Member at Jounce Therapeutics Exercises Options Worth $324K benzinga.com - May 5 at 3:51 PM
	Board Member at Jounce Therapeutics Exercises Options Worth $172K benzinga.com - May 4 at 7:17 PM
	Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options benzinga.com - May 4 at 2:17 PM
	Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options benzinga.com - May 4 at 2:17 PM
	Jounce Therapeutics Announces Closing of Tender Offer finance.yahoo.com - May 3 at 11:14 PM
	JNCE Jounce Therapeutics, Inc. seekingalpha.com - April 29 at 2:33 AM
	The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable finance.yahoo.com - April 17 at 1:51 PM
	What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday? benzinga.com - March 29 at 6:43 PM
	JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders markets.buffalonews.com - March 27 at 5:48 PM
	Buyout Offer Sends Jounce Jumping 20% msn.com - March 27 at 5:48 PM
	Jounce Therapeutics Shares Rally on Buyout Deal >JNCE marketwatch.com - March 27 at 12:47 PM
	Jounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCE marketwatch.com - March 27 at 12:47 PM
	Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs finance.yahoo.com - March 27 at 12:47 PM
	Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm benzinga.com - March 23 at 9:08 PM
	Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics 247wallst.com - March 17 at 7:18 PM
	Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer finance.yahoo.com - March 16 at 7:06 PM
	Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences finance.yahoo.com - March 16 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adaptimmune Therapeutics

NASDAQ:ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Aptose Biosciences

NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Gamida Cell

NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Jounce Therapeutics

NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial